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Background: Epithelial cell adhesion molecule (EpCAM) is frequently expressed in breast cancer, and its expression has been
associated with poor prognosis. Breast cancer can be subdivided into intrinsic subtypes, differing in prognosis and response to
therapy.
Methods: To investigate the association between EpCAM expression and prognosis in the intrinsic subtypes of breast cancer, we
performed immunohistochemical studies on a tissue microarray encompassing a total of 1365 breast cancers with detailed
clinicopathological annotation and outcomes data.
Results: We observed EpCAM expression in 660 out of 1365 (48%) cases. EpCAM expression varied significantly in the different
intrinsic subtypes. In univariate analyses of all cases, EpCAM expression was associated with a significantly worse overall survival. In
the intrinsic subtypes, EpCAM expression was associated with an unfavourable prognosis in the basal-like and luminal B HER2þ
subtypes but associated with a favourable prognosis in the HER2 subtype. Consistently, specific ablation of EpCAM resulted in
increased cell viability in the breast cancer cell line SKBR3 (ER , PR , and HER2þ ) but decreased viability in the breast cancer cell
line MDA-MB-231 (ER , PR , and HER2 ).
Conclusion: The differential association of EpCAM expression with prognosis in intrinsic subtypes has important implications for
the development of EpCAM-targeted therapies in breast cancer.
The epithelial cell adhesion molecule (EpCAM, also designated
TACSTD1, CD326) is a type I transmembrane protein of 314
amino acids that is localised to the basolateral membrane in the
majority of normal epithelial tissues. The functional role of
EpCAM in cell adhesion was the focus of early studies, and
EpCAM has been demonstrated to be a calcium-independent
homophilic cell adhesion molecule (Litvinov et al, 1994). Recent
studies have also demonstrated a role for EpCAM in cell signalling
and carcinogenesis (Munz et al, 2004; Osta et al, 2004; Maetzel
et al, 2009). EpCAM is perhaps best known for the fact that it is
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expressed in the majority of human epithelial cancers, including
colorectal, breast, gastric, prostate, ovarian, and lung cancer
(Spizzo et al, 2004; Went et al, 2004). EpCAM was the first
human tumour-associated antigen to be identified with mono-
clonal antibodies (Herlyn et al, 1979) and was the first target of
monoclonal antibody therapy in humans (Sears et al, 1982).
EpCAM expression has also been used to enrich circulating
tumour cells before microscopic evaluation in the only FDA-
approved assay for detection of circulating tumour cells in breast
cancer (Cristofanilli et al, 2004). Finally, EpCAM-targeted
therapies remain under active investigation, and a recent report
highlighted at least seven different molecular therapies targeting
EpCAM in various cancer types, including breast, gastric, ovarian,
and lung cancer (Baeuerle and Gires, 2007). Particular effort is
being made for breast cancer patients, where EpCAM expression
appears to predict response to EpCAM-targeting antibodies
(Schmidt et al, 2010; Schmidt et al, 2012).
EpCAM expression in primary cancer specimens has been
associated with a favourable prognosis in some cancer types and an
unfavourable prognosis in other cancer types. For instance,
EpCAM expression in primary breast and ovarian cancers as
measured by immunohistochemistry is associated with poor overall
survival (OS; Spizzo et al, 2002; Spizzo et al, 2004; Spizzo et al,
2006; Schmidt et al, 2008), while EpCAM expression in colorectal
and gastric cancer is associated with more favourable prognosis
(Songun et al, 2005; Went et al, 2006). All of these studies were
performed using standardised assay conditions and several used
tissue microarrays (TMAs); taken together, these studies include
specimens from over 6000 cancer patients. This differential
association between EpCAM expression and prognosis is paralleled
in functional studies of EpCAM biology performed both in vitro
and in vivo. Loss-of-function analyses using RNA interference
suggest that EpCAM expression is associated with increased
invasion in breast cancer (Osta et al, 2004; Sankpal et al, 2009a, b,
2011), and gain-of-function analyses in colorectal and lung cancer
suggest that EpCAM expression is associated with decreased cancer
invasion (Basak et al, 1998; Tai et al, 2007). Moreover, in breast
cancer cell lines, the impact of EpCAM expression on proliferation
has been recently shown to depend on the epithelial and
mesenchymal phenotype of these cells (Martowicz et al, 2012).
Taken together, these studies suggest that the impact of EpCAM
expression on cancer biology may be context-dependent (reviewed
in van der Gun et al, 2010).
Breast cancer is a heterogeneous disease. Recent advances in
molecular biology, including the development of sophisticated
techniques for gene expression profiling, have established a new
taxonomy of breast cancer, defining the breast cancer intrinsic
subtypes (Perou et al, 2000). This new taxonomy has had a
profound impact on the clinical management of breast cancer, as
the intrinsic subtypes differ markedly in prognosis and response to
therapy. As gene expression profiling data are not always available,
a recent international consensus conference defined an approx-
imation, using immunohistochemical expression of oestrogen
receptor (ER) and progesterone receptor (PR), overexpression,
and/or amplification of the human epidermal growth factor
receptor 2 (HER2) and Ki67 labelling index to approximate the
breast cancer intrinsic subtypes (Goldhirsch et al, 2011).
Although EpCAM expression is associated with poor prognosis
in breast cancer, the impact of EpCAM expression on prognosis in
the breast cancer intrinsic subtypes remains to be defined. As noted
above, this is an important question, as the breast cancer intrinsic
subtypes have distinct biology, and there is strong evidence
suggesting that the impact of EpCAM in cancer is context-
dependent. To definitively address this question, we performed
immunohistochemical studies on a breast cancer TMA encom-
passing a total of 1365 breast cancer cases with detailed clinical
annotation and outcomes data. A better understanding of the
relationship between EpCAM expression and prognosis in
the breast cancer intrinsic subtypes has important implications
for the design and successful application of molecular therapies
targeting EpCAM in breast cancer.
MATERIALS AND METHODS
Tissue microarray. We used a TMA encompassing a total of 2020
breast cancer tissue punches from 1579 formalin-fixed and
paraffin-embedded tumour samples. These samples were collected
from patients diagnosed with primary breast cancer between 1985
and 2007 at the University of Basel and the Viollier Institute in
Basel, Switzerland. Of these 2020 tissue punches, a total of 1365
cases were evaluable for our study. The tissue samples were
Table 1. Basic demographic data for 1365 evaluable breast cancer cases
Mean tumour size (mm) 31.0
Mean age at diagnosis (years) 63.5
Tumour stage
Number (n) %
pT1 364 26.7
pT2 728 53.4
pT3 104 7.6
pT4 169 12.3
Lymph node involvement
pN0 701 51.5
pN1 529 38.8
pN2 132 9.7
Tumour grade
1 318 23.3
2 551 40.4
3 496 36.3
Histological subtype
Invasive ductal 977 71.6
Invasive lobular 187 13.7
Mucinous 38 2.8
Apocrine 17 1.2
Cribriform 41 3.0
Papillary 18 1.3
Medullary 43 3.2
Other 43 3.2
Intrinsic subtype
Luminal A (ERþ and/or PRþ , HER2 , Ki-67o14%) 213 15.6
Luminal B (HER2-negative) ERþ and/or PRþ , HER2 ,
Ki-67X14%)
673 49.3
Luminal B (HER2-positive) (ERþ and/or PRþ , HER2þ ) 154 11.3
HER2 type (ER or PR , HER2þ ) 111 8.2
Basal-like (ER , PR , HER2 ) 213 15.6
Abbreviations: ER¼oestrogen receptor; HER2¼ human epidermal growth factor receptor
2; pr¼progesterone receptor.
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brought into a TMA format as previously described (Bubendorf
et al, 2001). Briefly, 0.6-mm tissue cylinders were punched out of
donor tumour tissue blocks and transferred into a recipient
paraffin block using a semi-automated tissue arrayer. Each TMA
contained a number of tumour punches ranging from 159 to 522.
Histopathological data were obtained from the original pathology
reports, and patient outcomes data were obtained from the Cancer
Registry of Basel or from the patient’s attending physician.
Retrieval of tissue and clinical data was performed in accordance
with the regulations of the local institutional review boards, with
specific attention to ethical standards and patient confidentiality.
Immunohistochemistry. Immunohistochemical staining of the
TMA was performed as described previously (Tapia et al, 2011).
For EpCAM immunohistochemistry, 4 mm sections of the TMA
blocks were incubated overnight with a primary anti-EpCAM
monoclonal antibody (1 : 800; clone VU-1D9, Novocastra,
Newcastle, UK) after heat-induced antigen retrieval. Standard
ABC-technique (ABC-Elite-Kit, Vector Laboratories, Burlingham,
CA, USA) was used for immunostaining, and diaminobenzidine
was used as chromogen. Counterstaining was performed with
hematoxylin solution. The staining intensity of ER, PR, and HER2
was scored as previously described (Tapia et al, 2011). EpCAM
expression was quantified using the modified Histo-score
(H-score) (McCarty et al, 1985), with a range of possible scores
from 0–300. Frequency and staining intensity of EpCAM on
tumour cells were analysed, and EpCAM expression was
Figure 1. Representative photographs of EpCAM expression in breast
cancer. (A) Strong membranous expression in 100% of tumour cells.
(B) Negative expression on tumour cells with positive expression in
normal mammary glands as an internal positive control. Original
magnification  400. A full color version of this figure is available at the
British Journal of Cancer online.
Table 2. Association between EpCAM expression and clinicopathological
parameters
Clinicopathological parameter
EpCAM-
positive
EpCAM-
negative P value
Mean tumour size (mm) 34.2 27.8 o0.0001
Mean age age at diagnosis (years) 63.7 63.3 0.6220
Tumour stage o0.0001
pT1 132 36.3 232 63.7
pT2 366 50.3 362 49.7
pT3 65 62.5 39 37.5
pT4 97 57.4 72 42.6
Lymph node involvement 0.0023
pN0 329 46.9 372 53.1
pN1 248 46.9 281 53.1
pN2 83 62.9 49 37.1
Tumour grade o0.0001
1 99 31.1 219 68.9
2 234 42.5 317 57.5
3 327 65.9 169 34.1
Oestrogen receptor o0.0001
ERþ 439 42.9 583 57.1
ER 221 65.2 118 34.8
HER2 0.0298
HER2þ 144 54.3 121 45.7
HER2 516 46.9 584 53.1
Ki67 o0.0001
Ki67þ 593 55.4 477 44.6
Ki67 66 23.0 221 77.0
Abbreviations: EpCAM¼epithelial cell adhesion molecule; ER¼oestrogen receptor;
HER2¼ human epidermal growth factor receptor 2; PR¼progesterone receptor.
Table 3. Association between EpCAM expression and histological
subtype
EpCAM-
positive
EpCAM-
negative P-value
Histological subtype n % n % o0.0001
Invasive ductal 496 50.8 481 49.2
Lobular 48 25.7 139 74.3
Mucinous 20 52.6 18 47.4
Apocrine 13 76.5 4 23.5
Cribiform 12 29.3 29 70.7
Papillary 12 66.7 6 33.3
Medullary 36 83.7 7 16.3
Other 23 53.5 20 46.5
Abbreviation: EpCAM¼ epithelial cell adhesion molecule.
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dichotomised into two groups according to the frequency
distributions of the H-scores, using a cut-off score of X100
(H-score 0–99¼ negative/low expression and 100–300¼ positive
expression).
Statistical analysis. The distribution of patient and clinical
characteristics between EpCAM-positive and EpCAM-negative
tumours was compared using the Chi-square test, Wilcoxon’s rank
sum test, or two-sample t-test, as appropriate. OS was defined as
the time from the first operation to death due to any cause.
Survivors were censored at the date of last contact. Survival curves
by EpCAM status were estimated using the Kaplan–Meier product-
limit method and compared by log-rank test. Univariate Cox
proportional hazard models were fit to identify factors significantly
related to OS. To assess whether EpCAM was an independent
predictor of survival, a multivariate Cox model was constructed to
adjust other patient/clinical characteristics that were significant
in the univariate analyses. Two-way interaction terms between
EpCAM and other factors in the multivariate Cox model were also
assessed. All analyses were two-sided and significance was set at a
P-value of 0.05. Statistical analyses were performed using SAS
(SAS Institutes, Cary, NC, USA).
Cell culture. All breast cancer cell lines were obtained from
the American Type Culture Collection (Rockville, MD, USA).
MCF-10A cells were grown in DMEM/F12 medium supplemented
with 5% donor horse serum, 20 ngml 1 epidermal growth factor,
10 mgml 1 insulin, 100 mgml 1 hydrocortisone, and 1 ngml 1
cholera toxin. MDA-MB-231 and SKBR3 cells were grown in
DMEM medium supplemented with 10% FBS.
Antibodies and western blot analysis. Western blotting was
performed by standard procedures. Cell lysates were harvested
with RIPA buffer (50mM Tris HCl pH 7.4, 150mM NaCl,
2mM EDTA, 1% NP40, 0.1% SDS, 0.5% sodium deoxycholate,
1 complete protease inhibitors (Roche, Basel, Switzerland), and
phosphatase inhibitors, including sodium orthovanadate (Sigma,
St. Louis, MO, USA) and sodium fluoride (Sigma). Protein
concentration was measured using the BCA protein assay (Thermo
Scientific, Rockford, IL, USA). Equal loading of each sample of
protein (20 mg) was then subjected to SDS–PAGE (NuPAGE,
Invitrogen, Carlsbad, CA, USA) and transferred by electrophoresis
to a PVDF membrane. Antibodies against EpCAM C-10 (Santa
Cruz, Dallas, TX, USA) and Actin C-4 (Santa Cruz) were used at
ratios of 1 : 1000 and 1 : 5000, respectively, and detection was
performed with HRP-conjugated antisera and chemiluminescence
(Thermo Scientific, Rockford, IL, USA).
Lentiviral shRNA production and infections. Lentiviral vectors
encoding shRNAs specific for EpCAM as well as control GFP
sequences are part of The RNAi Consortium shRNA Library
(http://www.broadinstitute.org/rnai/trc). Sequences are as follows:
for shRNA EpCAM, 50GCAAATGGACACAAATTACAA30; and
for shRNA GFP, 50ACAACAGCCACAACGTCTATA30. Lentivirus
was produced by transfection of 293T cells with vectors encoding
gene-specific shRNAs (1mg) together with the packaging plasmids
encoding D8.9 and VSV-G using Fugene 6 (Roche). Culture
supernatants containing lentivirus were collected 48 and 72 h post
transfection. Virus was pooled and stored at  80 1C. Cells were
infected using a 1 : 11 dilution of virus in polybrene-containing
media. Following centrifugation at 1000 g for 15min, all breast
cancer cell lines were selected in puromycin (1 mgml 1) starting
24 h post infection. Viability assays were conducted 10 days
post infection using crystal violet. Protein lysates were harvested
72 h following shRNA expression to evaluate gene suppression.
Crystal violet cell proliferation assay. Cell proliferation assays
were performed in six-well plates. Cells were plated to achieve 50%
cell density on day of lentiviral infection. Puromycin selection 24 h
post infection was performed. On day 3 post infection, cells were
re-plated onto 60-mm dishes. On day 10, plates were stained with
crystal violet (crystal violet 0.2%, ethanol 2%) and photographed.
The crystal violet stain was then solubilised in 1% SDS solution
with incubation on a shaker for 1 h at room temperature. Optical
density was measured at 595 nm. Cell proliferation effects for SK-
BR-3 after exposure to EpCAM shRNA and GFP shRNA were
analysed as percentages. The solubilised dye from the EpCAM
shRNA sample was read at 100% and then serially diluted to 75%,
50%, and 25% to generate a crystal violet curve to extrapolate the
percentage for the GFP shRNA sample. Data presented are
representative of three independent experiments.
RESULTS
The expression of EpCAM could be evaluated in 1365 cases in this
cohort. Basic demographic information for the 1365 evaluable
cases is presented in Table 1. The mean age at diagnosis was
63.5 years (range 27–101 years), and the mean follow-up time was
80.8 months (range 1–263 months). Expression of EpCAM
was confined to the membrane of breast cancer cells in all the
cases (Figure 1). EpCAM expression was defined using the
H-score, a score integrating the intensity of EpCAM staining,
and the percentage of breast cancer cells expressing EpCAM. With
an H-score threshold of X100, a total of 660 breast cancers
Table 4. Association between EpCAM expression and breast cancer
intrinsic subtype
EpCAM-
positive
EpCAM-
negative P-value
Intrinsic subtype n % n % o0.0001
Luminal A (ERþ and/or PRþ ,
HER2 , Ki-67o14%)
48 22.5 165 77.5
Luminal B (HER2-negative) (ERþ
and/or PRþ , HER2 , Ki-67X14%)
332 49.3 341 50.7
Luminal B (HER2-positive) (ERþ
and/or PRþ , HER2þ )
63 40.9 91 59.1
HER2 type (ER , PR , HER2þ ) 81 73.0 30 27.0
Basal-like (ER , PR , HER2 ) 136 63.8 77 36.2
Abbreviations: EpCAM¼ epithelial cell adhesion molecule; ER¼oestrogen receptor;
HER2¼human epidermal growth factor receptor 2; PR¼progesterone receptor.
Table 5. Univariate analyses for all cases, and by intrinsic subtype, for the
effect of EpCAM expression on overall survival
EpCAM expression, all cases Hazard ratio (95% CI) P-value
EpCAM-positive 1.402 (1.178–1.668) 0.0001
EpCAM expression, by intrinsic subtype
Luminal A 1.487 (0.817–2.707) 0.1937
Luminal B (HER2 ) 1.208 (0.936–1.560) 0.1464
Luminal B (HER2þ ) 2.400 (1.451–3.971) 0.0006
HER2 type 0.374 (0.217–0.644) 0.0004
Basal-like 1.634 (1.070–2.497) 0.0231
Abbreviations: EpCAM¼ epithelial cell adhesion molecule; CI¼ confidence interval;
HER2¼human epidermal growth factor receptor 2.
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(48.3%) expressed EpCAM. Consistent with previous studies,
EpCAM expression was significantly associated with greater
tumour size, lymph node involvement, tumour stage, and tumour
grade (Table 2; Gastl et al, 2000; Schmidt et al, 2008; Agboola et al,
2011; Spizzo et al, 2011). EpCAM expression was significantly
higher in ER-negative (ER ) cases (EpCAM expression 65.1% in
ER cancers vs 42.9% in ERþ cancers, Po0.0001, Table 2) and in
HER2þ cases (EpCAM expression 54.3% in HER2þ cancers vs
46.9% in HER2 cancers, P¼ 0.0298, Table 2). EpCAM expres-
sion was also significantly associated with histological subtype
(Po0.0001); EpCAM expression was higher in the invasive ductal
(51%) and medullary (84%) histological types and lower
in the invasive lobular (26%) and cribiform (29%) subtypes
(Table 3). EpCAM expression varied significantly between the
intrinsic subtypes of breast cancer, as defined by the St. Gallen
Consensus Conference criteria (Goldhirsch et al, 2011). EpCAM
overexpression was highest in the basal-like (64%) and HER2
(73%) subtypes and lowest in the luminal A subtype (23%,
Po0.0001; Table 4). Furthermore, EpCAM expression was highly
correlated with the expression of Ki-67 in all of the intrinsic
subtypes except for luminal A (data not shown).
In univariate survival analyses, we could demonstrate that breast
cancer cases with EpCAM expression had a significantly worse OS
(hazard ratio (HR)¼ 1.402, P¼ 0.0001; Table 5 and Figure 2).
In univariate analyses of the breast cancer intrinsic subtypes,
EpCAM expression was associated with significantly decreased OS
in the luminal B HER2þ subtype (HR¼ 2.4, P¼ 0.0006) and the
basal-like subtype (HR¼ 1.634, P¼ 0.023; Table 5 and Figure 2).
The luminal A and the luminal B HER2 subtypes also showed a
trend towards decreased OS with EpCAM expression (Table 5 and
Figure 2), but this was not statistically significant. Of particular
interest, EpCAM expression was significantly associated with
improved OS in the HER2 subtype (HR¼ 0.374, P¼ 0.0004;
Table 5 and Figure 2). In multivariate analysis, after adjusting
for age, tumour size, lymph node involvement, tumour grade, and
intrinsic subtype, EpCAM expression remained significantly
associated with improved OS in the HER2 subtype (HR¼ 0.329,
Po0.0001) and showed a trend toward decreased OS in the
luminal B HER2þ subtype (HR¼ 1.546, P¼ 0.094) and the basal-
like subtype (HR¼ 1.437, P¼ 0.096; Table 6).
Previously, we demonstrated that specific ablation of EpCAM
significantly decreased proliferation of the basal-like breast cancer
cell line MDA-MB-231, with minimal impact on proliferation of
the breast epithelial cell line MCF10A. Given the differential
association between EpCAM and prognosis in the HER2 and basal-
like intrinsic subtypes of breast cancer, we sought to evaluate the
impact of EpCAM expression on proliferation in representative
breast cancer cell lines in vitro. We specifically ablated EpCAM
expression in the MCF10A, MDA-MB-231, and SKBR3 (ER /
PR /HER2þ ) cell lines (Figure 3). Of note, we not only confirmed
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Figure 2. Kaplan–Meier survival curves. (A) Kaplan–Meier survival curve for overall survival depending on EpCAM overexpression (univariate
analysis). (B–F) Kaplan–Meier survival curves for overall survival depending on EpCAM overexpression for indivdual intrinsic breast cancer
subtypes.
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that specific ablation of EpCAM decreases proliferation in the
MDA-MB-231 cell line but also demonstrated that specific ablation
of EpCAM results in an almost four-fold increase in proliferation
in the SKBR3 cell line, consistent with the IHC analyses.
DISCUSSION
EpCAM is commonly expressed in breast cancer, and EpCAM
expression in primary breast cancers has been widely reported to
be associated with poor prognosis. However, breast cancer is a
heterogeneous disease, and the impact of EpCAM expression on
prognosis in the breast cancer intrinsic subtypes remains to be
investigated. Here, we studied EpCAM expression in a large cohort
of primary breast cancers, with a particular focus on defining the
potential associations between EpCAM expression and the breast
cancer intrinsic subtypes, as defined by the most recent St. Gallen
Consensus Conference (Goldhirsch et al, 2011). Of note, we
demonstrate for the first time that EpCAM expression varies
significantly between the intrinsic subtypes of breast cancer,
ranging from 22.5% in luminal A to 73.0% in the HER2 subtype.
We have also made the surprising observation that the impact of
EpCAM expression on prognosis in breast cancer is dependent on
intrinsic subtype. In the basal-like and luminal B HER2þ subtypes,
EpCAM expression is associated with an unfavourable prognosis;
in the HER2 subtype, EpCAM expression is associated with a
favourable prognosis.
Our study confirms the results of previous studies demonstrat-
ing that EpCAM expression is associated with tumour size, lymph
node involvement, tumour grade, and prognosis in breast cancer
(Tandon et al, 1990; Schmidt et al, 2008; Spizzo et al, 2011;
Agboola et al, 2011). In addition, we observed that EpCAM
expression is inversely associated with expression of ER
(Po0.0001) and positively associated with HER2 expression
(P¼ 0.0298), findings that have been previously reported by others
(Spizzo et al, 2002; Schmidt et al, 2008; Agboola et al, 2011).
Although multiple studies have suggested that EpCAM expression
is an independent predictor of disease-free survival and OS (Spizzo
et al, 2002; Schmidt et al, 2008; Agboola et al, 2011), we did not
observe this finding in our collective (P¼ 0.7824 in multivariate
analysis). This may be related to the strong association we observed
between EpCAM expression and traditional predictors of prog-
nosis in breast cancer, such as tumour size, lymph node
involvement, tumour grade, ER status, HER2 status, intrinsic
subtype, and Ki67 labelling index.
This study is the first to evaluate the association between
EpCAM expression and prognosis in the intrinsic subtypes of
breast cancer. To do this, we used well-recognised criteria for
approximating the intrinsic subtypes using immunohistochemical
criteria (ER status, PR status, HER2, Ki67 labelling index). Because
of the large sample size (n¼ 1365 cases), we had adequate power to
meaningfully evaluate potential associations between EpCAM
expression and prognosis in the breast cancer intrinsic subtypes,
demonstrating a surprising differential impact on prognosis
between the basal-like, luminal B HER2þ , and HER2 subtypes.
Recently, Agboola et al (2011) investigated the impact of EpCAM
expression on prognosis in a cohort of 726 primary breast cancer
cases. They observed that EpCAM expression is associated with
tumour size and tumour grade and is an independent predictor of
disease-free and OS. They also evaluated the potential association
between EpCAM expression and other biomarkers, including ER,
HER2, p53, CK5/6, and CK14. Of note, they defined basal-like
breast cancer as CK5/6 and/or CK14-positive and demonstrated
that EpCAM expression is an independent predictor of poor
prognosis in basal-like breast cancer. Although Agboola et al
(2011) use a different criteria to define basal-like breast cancer,
their results are consistent with the results reported here,
confirming the importance of EpCAM expression in this intrinsic
subtype. EpCAM-targeted therapies may be particularly appro-
priate in this subtype, because EpCAM is expressed in the majority
of basal-like breast cancers and treatment options are otherwise
limited for patients with basal-like breast cancer.
One limitation of our study is that we defined breast cancer
intrinsic subtype using the St. Gallen Consensus Conference
criteria. These criteria provide only an approximation of intrinsic
subtype. For instance, not all triple-negative breast cancers
identified by immunohistochemistry correspond to the intrinsic
basal-like subtype. Although there is an approximately 80% overlap
between triple-negative and intrinsic basal-like subtype, triple-
negative cancers also include special histological subtypes, such as
medullary and adenoid cystic carcinoma with a much lower risk of
recurrence (Goldhirsch et al, 2011; Penault-Llorca and Viale,
2012). Thus, using the triple-negative phenotype as an approxima-
tion for basal-like breast cancer may underestimate the impact of
EpCAM on this intrinsic subtype.
Table 6. Multivariate analysis for the effect of clinicopathological
parameters and EpCAM expression on overall survival
Clinicopathological parameter
Hazard ratio
(95% CI)
P-value
Age (per 1 year ) 1.037 (1.029–1.044) o0.0001
Tumour stage
pT1 (reference) 1
pT2 1.603 (1.226–2.097) 0.0006
pT3 2.089 (1.437–3.037) 0.0001
pT4 2.208 (1.581–3.083) o0.0001
Lymph node involvement
pN1 (reference) 1
pN1 1.427 (1.168–1.745) 0.0005
pN2 2.782 (2.103–3.680) o0.0001
Tumour grade
BRE grade 1 (reference) 1
Grade 2 1.631 (1.230–3.454) 0.0006
Grade 3 2.571 (1.914–3.454) o0.0001
Intrinsic subtype
Luminal A (reference) 1
Luminal B (HER2 ) 1.081 (0.792–1.475) 0.6237
Luminal B (HER2þ ) 1.263 (0.864–1.848) 0.2283
HER2 type 1.193 (0.784–1.815) 0.4097
Basal-like 2.031 (1.419–2.906) 0.0001
EpCAM expression, by intrinsic subtype
Luminal A 1.404 (0.771–2.557) 0.2666
Luminal B (HER2 ) 0.860 (0.660–1.119) 0.2614
Luminal B (HER2þ ) 1.546 (0.928–2.575) 0.0941
HER2 type 0.329 (0.190–0.570) o0.0001
Basal-like 1.437 (0.938–2.201) 0.0958
Abbreviations: EpCAM¼ epithelial cell adhesion molecule; BRE¼Elsten’s modification of
Bloom and Richardson; CI¼ confidence interval; HER2¼ human epidermal growth factor
receptor 2.
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In this study, we demonstrate, for the first time, that EpCAM is
highly expressed in the HER2 subtype (73.0%). Surprisingly,
EpCAM expression in the HER2 subtype was associated with a
significantly improved OS (P¼ 0.0004). Consistent with these
findings were the results of in vitro studies, where downregulation
of EpCAM with shRNA led to increased viability and cell growth in
the SKBR3 breast cancer cell line. This cell line corresponds to the
HER2 subtype (ER- and PR , HER2þ ), and its increased viability
after specific ablation of EpCAM supports our finding that
EpCAM is associated with favourable prognosis in this breast
cancer subtype. The reason for this differential association with
survival in the HER2 subtype is not known to date. Of note, a study
by Spizzo et al (2002) suggests that concurrent EpCAM and HER2
expression may be associated with an additive negative impact on
disease-related OS. In their study, however, the HER2þ cases were
evaluated as a single group. The current taxonomy of breast cancer
suggests that HER2þ cases should be divided into two subtypes,
the luminal B HER2þ subtype (ERþ and/or PRþ , HER2þ )
and the HER2 subtype (ER and PR , HER2þ ). In addition,
Spizzo et al (2002) observed simultaneous expression of HER2 and
EpCAM in a much smaller number of cases (13.2% vs 54.3% in
our study). However, our study contains significantly more
patient samples, and for this reason, our observations might have
more power in this regard. Our data clearly suggest that EpCAM
expression in the HER2 subtype is associated with a favourable
prognosis. Therefore, targeting EpCAM in this group of
patients should be performed with caution, particularly if the
therapy is aimed at abrogating EpCAM-dependent signalling
pathways.
A second limitation of this study is that we evaluated expression
of extracellular EpCAM only. Recent evidence suggests that
EpCAM can be cleaved at the cell surface, with nuclear
translocation of the intracellular portion (Maetzel et al, 2009).
Although we believe that expression of extracellular EpCAM is a
surrogate for EpCAM-dependent signalling, staining with an
antibody to the intracellular portion may provide better insight
into the extent of EpCAM-dependent signalling. Further studies
with a particular emphasis on defining EpCAM signalling may
provide additional insights into the relationship between EpCAM
expression and breast cancer biology.
In summary, we demonstrate that EpCAM expression is
variably expressed in the breast cancer intrinsic subtypes and is
differentially associated with OS in the luminal B HER2þ , HER2,
and basal-like intrinsic subtypes. This result is consistent with the
hypothesis that the impact of EpCAM expression on cancer
biology is context-dependent and has important implications for
the rational development of novel therapeutics targeting EpCAM
currently under clinical investigation.
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